Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort.
Raphael
R
Itzykson
Sylvain
S
Thépot
Bruno
B
Quesnel
Francois
F
Dreyfus
Christian
C
Recher
Eric
E
Wattel
Claude
C
Gardin
Lionel
L
Adès
Pierre
P
Fenaux
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use*; D015331:Cohort Studies; D057176:Compassionate Use Trials / Q000379:methods / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine